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Introduction
Cefepime (I) is a fourth-generation cephalosporin antibiotic that was developed as a broad range activity antibiotic in the 1990s.
1,2 Cefepime was found to be particularly effective against pseudomonas aeruginosa strains which exhibited resistance against other cephalosporin antibiotics, such as ceftazidime and cefotaxime. 3 Cefepime has greater activity against Gram-negative bacteria compared to other cephalosporins, 4 and is used to treat a wide degree of infectious diseases. 5 However, cefepime is unstable and slowly degrades over time.
The degradation rate is greatly increased at higher temperatures (25-37 ˚C) and in an aqueous solution, the loss affects the antibiotic activity significantly enough that it is recommended cefepime not be used for clinical use in aqueous conditions at >25 ˚C for more than a few hours. 6 
I II
The impurity N-methyl pyrrolidine (NMP, II) may be present in cefepime samples as a result of degradation of the drug. NMP has been reported as having unknown toxicity by US Environmental Protection Agency, 7 and the potential for toxicity to patients receiving the drug is yet to be determined. An experimental study performed on monkeys, in which NMP (50 mg/kg) was administered over 28-30 consecutive days resulted in them developing esotropia and ataxia. 5 The dosage of NMP used in the study was much greater than the amount expected to be received in a daily dose of cefepime (~6g) administered to patients, but the presence of the potentially harmful impurity is still undesirable. It has been reported that an increase in the NMP level is proportional to the decline in the antibiotic potency of cefepime. 8, 9 Monitoring the level of NMP in cefepime is, therefore, important for ensuring drug quality for clinical use and a threshold concentration of NMP in cefepime has been set at 0.3 % (w/w).
The determination of NMP in cefepime presents an analytical challenge because of the rapid degradation of cefepime to NMP in aqueous solution above 4 ˚C and outside the pH range 4-
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6, resulting in the presence of higher levels of NMP in solution than are present in the solid cefepime sample. At present, there are four main techniques employed for NMP determination: high performance liquid chromatography (HPLC), ion chromatography (IC), capillary electrophoresis (CE) and gas chromatography (GC). 5, 6, [8] [9] [10] There are limitations associated with all these techniques. The HPLC method requires a mobile phase of pH 2 and the IC method uses a column temperature of 40 ˚C; both of these conditions could lead to degradation of cefepime and reduce measurement accuracy. Poor detection and quantification limits for CE and the use of a solvent with high toxicity, pyridine, to extract NMP for the GC technique makes these methods less desirable for routine analysis of NMP. The preparation of a cefepime sample for analysis therefore requires either the extraction of the NMP from the cefepime matrix to minimise the contribution from NMP produced by degradation in solution prior to analysis, or rapid analysis of the sample solution before significant degradation occurs.
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A further challenge in the determination of NMP in cefepime is that the singly and doubly protonated cefepime generated by electrospray mass spectrometry (ESI-MS) are readily fragmented in the intermediate pressure region of the mass spectrometer interface by collision-induced dissociation (CID), also known as in-source CID, to form protonated NMP.
The NMP generated by CID interferes with response from the protonated NMP formed from NMP present in the cefepime sample, since NMP resulting from the sample and via CID cannot be distinguished by mass spectrometry alone.
Field asymmetric waveform ion mobility spectrometry (FAIMS) is a rapid gas phase separation technique in which the transmission of ions is based on differences in mobility in low and high electric fields; a separation dimension that is highly orthogonal to m/z. 12-14 A FAIMS device is therefore able to transmit ions of a selected differential mobility, in the similar way that a quadrupole mass analyser may be used to transmit ions of a selected m/z.
The combination of a FAIMS device with electrospray ionization and mass spectrometry (ESI-FAIMS-MS) has been shown to improve selectivity and limits of detection/quantification without loss of linear dynamic range. [15] [16] [17] [18] Miniaturised chip-based FAIMS-MS has been used for a range of pharmaceutical applications, including the separation of pharmaceutical excipients 17 and isobaric potentially genotoxic impurities, 18 and the reduction of chemical noise in the analysis of biofluids. [16] [17] In this paper, the potential for combining a miniaturised FAIMS device with direct infusion-
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ESI-MS to remove interference from NMP fragment ions generated by CID in the mass spectrometer interface is demonstrated, enabling the determination of NMP in cefepime.
Materials and Methods

Chemicals
HPLC grade methanol, water and formic acid were obtained from Fisher Scientific (Loughborough, UK). Cefepime was obtained from Orchid Chemicals and Pharmaceuticals Limited (Chennai, India). N-methyl pyrrolidine was supplied by Sigma-Aldrich Limited (Gillingham, UK).
Sample Preparation
NMP standards
A stock solution of NMP (1 mg/ml) was prepared in methanol/water (50:50). The stock was subsequently diluted to 1 μg/ml with methanol/water (50:50) + 0.1% formic acid. A series of dilutions in the range 0.01 -1.0 μg/ml (2-fold at each step) were used for standard addition experiments.
Cefepime samples
Fresh solutions of cefepime (5 mg/ml) were prepared in methanol 10 minutes prior to analysis. A single 100-fold dilution of the cefepime solution (to 50 μg/ml, 10μl) in methanol/water (50:50) + 0.1% formic acid (990 μl), or NMP solution (500 μl + 490 μl diluent) for the standard additions calibration, was performed immediately before analysis.
NMP and methanol/water (50:50) + 0.1% formic acid solutions were combined before preparation of cefepime samples so that weighing and dissolving cefepime, and transferring an aliquot of cefepime solution (10 μl) to the diluted NMP solution were the only steps performed between acquisitions.
Instrumentation
Sample solutions and standards were infused (15 μl/min) using a syringe pump into the Scanning FAIMS experiments were carried out in the compensation field (CF) range -2 to 5
Td (scan speed 0.5 Td/s ) at each dispersion field (DF), which was incremented in the range 180-230 Td in 5 Td steps to determine optimum conditions to separate NMP from cefepime.
Static FAIMS experiments used a fixed CF (0 Td) and DF (180 Td) to pre-select NMP generated in the ESI ion source. Cefepime solutions were infused into the source and data acquired for 2 min/sample. Data were acquired using Agilent MassHunter Acquisition B.05.00 and processed using Agilent MassHunter Qualitative Analysis B.05.00. Microsoft
Excel 2010 was used to produce CF plots. 
Results and Discussion
Cefepime degrades rapidly in solution, so the time between preparing a cefepime solution for analysis and acquiring data for the determination of NMP can potentially influence the accuracy of the quantification of NMP in the original cefepime sample. Sample preparation and analysis time therefore needs to be minimised, making the direct infusion of the sample into the ESI source of a mass spectrometer a potentially rapid alternative to conventional approaches for NMP determination. However, the conditions used for ESI-MS may lead to fragmentation of cefepime ions to protonated NMP in the mass spectrometer interface, which will increase the NMP response. The potential of FAIMS to separate the response for NMP in the original cefepime sample from NMP generated by in-source CID was therefore investigated. sample and CID of the cefepime ion generated by ESI, preventing the direct determination of NMP by ESI-MS. It would be possible, in principle, to subtract the percentage contribution to the total NMP response from in-source CID in order to determine the NMP in cefepime, but
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The FAIMS dispersion field (DF) and compensation field (CF) characteristics of protonated cefepime and NMP were investigated to determine whether these ions could be separated on the basis of differences in their high field and low field mobility. Figure 4 shows the mass- The mass spectrum extracted from the FAIMS CF scan at a CF of 0 Td shows the protonated NMP to be the base peak in the mass spectrum ( Figure 5 ). There is a weak response from the protonated cefepime at this CF, because of the 1000 fold excess of the drug, but this is small compared to the relative responses for NMP and cefepime in the absence of a FAIMS separation. The FAIMS was operated in static mode (CF 0.1 Td, DF 180 Td) to selectively transmit NMP generated in the ESI ion source through the device for the determination of NMP in cefepime.
Cefepime solutions were infused into the source 10 minutes after preparation to avoid degradation in solution and data acquired with an analysis time of 2 min/sample from the start of the infusion. The limit of detection for NMP was estimated to be 0.11 mg/g in the cefepime sample, giving a limit of quantitation 0.36 mg/g, which is equivalent to 0.036%, well below the 0.3% threshold concentration for NMP in cefepime. The %RSD for replicate samples was 3.85% (n=6, 0.37 μg/ml) for NMP, with good linearity (R 2 0.9979) for standard additions in the range 0.005 -0.5 μg/ml. These preliminary quantitative data demonstrate the potential of direct ESI-FAIMS-MS for the determination of NMP in cefepime at, and below, the threshold concentration, subject to full validation of the method.
Conclusions
The formation of NMP by solution degradation and CID of cefepime in the intermediate pressure region of the mass spectrometer interface presents an analytical challenge for the determination of NMP in cefepime. The use of a FAIMS separation of NMP and cefepime ions prior to mass spectrometric analysis allows NMP in a cefepime sample to be distinguished from NMP ions generated by CID in the mass spectrometer interface. Direct infusion of a cefepime solution using ESI-FAIMS-MS is shown to be a rapid, selective method for the quantitative determination of NMP in cefepime with an LOQ well below the required 0.3 % threshold and good precision. The approach reported here for NMP in cefepime has potential for generic application to the direct determination of impurities present in other active pharmaceutical ingredients which fragment to yield the impurity ion by CID.
